Last updated: 07/16/2019 17:40:10

A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF MAPATUMUMAB ([HGS1012], A FULLY-HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH SORAFENIB AS A FIRST-LINE THERAPY IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Request patient level data
GSK study ID
200178
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF MAPATUMUMAB ([HGS1012], A FULLY-HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH SORAFENIB AS A FIRST-LINE THERAPY IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Trial description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF MAPATUMUMAB ([HGS1012], A FULLY-HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH SORAFENIB AS A FIRST-LINE THERAPY IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
25
Primary completion date:
2014-25-04
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Carcinoma, Hepatocellular
Product
mapatumumab, sorafenib
Collaborators
Not applicable
Study date(s)
July 2008 to April 2014
Type
Interventional
Phase
1

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Aurora, Colorado, United States, 80045
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gainsville, Florida, United States, 32610
Status
Study Complete
Contact us
Location
GSK Investigational Site
Los Angeles, California, United States, 90048
Status
Study Complete
Contact us
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Status
Study Complete
Contact us

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
2014-25-04
Actual study completion date
2014-25-04

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website